Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial

医学 血管内超声 急性冠脉综合征 冠状动脉造影 内科学 超声波 药物洗脱支架 心脏病学 支架 药品 放射科 外科 心肌梗塞 再狭窄 精神科
作者
Zhen Ge,Xiaofei Gao,Jing Kan,Xiangquan Kong,Guang‐Feng Zuo,Fei Ye,Nai‐Liang Tian,Song Lin,Zhizhong Liu,Yibing Shao,Yuquan He,Shangyu Wen,Qing Yang,Yong Xia,Zhengzhong Wang,Pingxi Xiao,Li Feng,Hesong Zeng,Song Yang,Yan Wang
出处
期刊:American Heart Journal [Elsevier BV]
卷期号:236: 49-58 被引量:17
标识
DOI:10.1016/j.ahj.2021.02.014
摘要

Current guidelines recommend administering dual antiplatelet therapy (DAPT) for 12 months to patients with acute coronary syndromes (ACS) and without contraindications after drug-eluting stent (DES) implantation. A recent study reported that 3 months of DAPT followed by ticagrelor monotherapy is effective and safe in ACS patients undergoing DES implantation compared with the standard duration of DAPT. However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor.The IVUS-ACS and ULTIMATE-DAPT is a prospective, multicenter, randomized, controlled trial designed to determine (1) whether IVUS-guided versus angiography-guided DES implantation in patients with ACS reduces the risk of target vessel failure (TVF) at 12 months and (2) whether ticagrelor alone versus ticagrelor plus aspirin reduces the risk of clinically relevant bleeding without increasing the risk of MACCE 1-12 months after the index PCI in ACS patients undergoing DES implantation guided by either IVUS or angiography. This study will enroll 3486 ACS patients eligible for DES implantation, as confirmed by angiographic studies. The patients who meet the inclusion criteria and none of the exclusion criteria will be randomly assigned in a 1:1 fashion to the IVUS- or angiography-guided group (first randomization). All enrolled patients will complete a 1-month course of DAPT with aspirin plus ticagrelor after the index PCI. Patients with no MACCEs or major bleeding (≥Bleeding Academic Research Consortium (BARC) 3b) within 30 days will be randomized in a 1:1 fashion to either the ticagrelor plus matching placebo (SAPT)group or ticagrelor plus aspirin (DAPT)group for an additional 11 months (second randomization). The primary endpoint of the IVUS-ACS trial is TVF at 12 months, including cardiac death, target vessel myocardial infarction (TVMI), or clinically driven target vessel revascularization (CD-TVR). The primary superiority endpoint of the ULTIMATE-DAPT trial is clinically relevant bleeding, defined as BARC Types 2, 3, or 5 bleeding, and the primary non-inferiority endpoint of the ULTIMATE-DAPT trial is MACCE, defined as cardiac death, myocardial infarction, ischemic stroke, CD-TVR, or definite stent thrombosis occurring 1-12 months in the second randomized population.The IVUS-ACS and ULTIMATE-DAPT trial is designed to test the efficacy and safety of 2 different antiplatelet strategies in ACS patients undergoing PCI with DES implantation guided by either IVUS or angiography. This study will provide novel insights into the optimal DAPT duration in ACS patients undergoing PCI and provide evidence on the clinical benefits of IVUS-guided PCI in ACS patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ABC完成签到,获得积分20
2秒前
原本发布了新的文献求助10
2秒前
dzy完成签到,获得积分20
3秒前
amber完成签到 ,获得积分10
3秒前
Green完成签到,获得积分10
5秒前
6秒前
小木子完成签到,获得积分10
8秒前
舟遥遥完成签到,获得积分10
9秒前
华仔应助大橙子采纳,获得10
11秒前
桐桐应助Bismarck采纳,获得10
15秒前
CLY完成签到,获得积分10
16秒前
17秒前
rita_sun1969完成签到,获得积分10
18秒前
研友_8K2QJZ完成签到,获得积分10
18秒前
蝴蝶完成签到 ,获得积分10
19秒前
ARIA完成签到 ,获得积分10
19秒前
大橙子发布了新的文献求助10
22秒前
Bismarck完成签到,获得积分20
23秒前
23秒前
爱笑子默完成签到,获得积分10
24秒前
24秒前
一点完成签到,获得积分10
26秒前
研友_VZG7GZ应助大葱鸭采纳,获得10
26秒前
DezhaoWang完成签到,获得积分10
27秒前
知犯何逆发布了新的文献求助10
28秒前
原本完成签到,获得积分10
28秒前
Bismarck发布了新的文献求助10
29秒前
苗条丹南完成签到 ,获得积分10
31秒前
yu完成签到 ,获得积分10
34秒前
skyleon完成签到,获得积分10
34秒前
无心的天真完成签到 ,获得积分10
35秒前
Engen完成签到,获得积分20
35秒前
36秒前
学术小垃圾完成签到,获得积分10
36秒前
dreamwalk完成签到 ,获得积分10
36秒前
黄淮科研小白龙完成签到 ,获得积分10
37秒前
齐嫒琳完成签到,获得积分10
39秒前
研友_Lav0Qn完成签到,获得积分10
39秒前
大橙子发布了新的文献求助10
40秒前
GreenT完成签到,获得积分10
40秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022